- Home
- MVST vs PHAT Comparison
MVST vs PHAT Comparison
Compare MVST & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MVST | PHAT |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 987.8M | 894.0M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | MVST | PHAT |
|---|---|---|
| Price | $1.54 | $11.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $6.00 | ★ $19.83 |
| AVG Volume (30 Days) | ★ 5.2M | 961.2K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 42.72 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $175,110,000.00 |
| Revenue This Year | $24.55 | $93.04 |
| Revenue Next Year | $17.08 | $58.91 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 216.93 |
| 52 Week Low | $1.37 | $2.21 |
| 52 Week High | $7.12 | $18.31 |
Technical Indicators
Market Signals| Indicator | MVST | PHAT |
|---|---|---|
| Relative Strength Index (RSI) | 40.28 | 56.66 |
| Support Level | $1.51 | $11.04 |
| Resistance Level | $2.40 | $11.90 |
| Average True Range (ATR) | 0.11 | 0.64 |
| MACD | 0.02 | 0.20 |
| Stochastic Oscillator | 50.00 | 81.11 |
Price Performance
Historical ComparisonAbout MVST Microvast Holdings Inc.
Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.